Pharmacogenomic (PGx) testing will help uncover your biological response to different medications.
CQuentia provides a comprehensive, industry-leading PGx test covering 43 genes and its 183 variants (mutation) addressing the response to over 24,000 medications and multiple conditions such as the patient’s risk to Malignant Hyperthermia, Pseudocholinesterase Deficiency, and the patient’s Thrombosis Profile.
CQuentia’s Pharmacogenomic testing program explore the patient’s unique individual genetic profile identifying how they will respond to the various medications used during and after surgery. CQuentia also defines when a patient has a genetic risk for malignant hyperthermia, a pseudocholinesterase deficiency or has a thrombosis risk. The combined view of medication efficacy and risk factors provides a greater level of patient detail that directly impacts the success of the surgical event.
We ensure that the results of our comprehensive pharmacogenomic (PGx) tests are made accessible at point-of-care. PGx guided medication management has shown to reduce narcotic use during surgery, decrease instances of post-operative side effects (such as nausea/vomiting) and improve post-operative pain scores.